greeksoup/ stock research

Angiodynamics (ANGO) Q3 FY2026 earnings: revenue $78 million, up 8.9% on the year

Angiodynamics Inc. (ANGO) reported revenue of $78 million for Q3 FY2026, the quarter ended 28 February 2026, up 8.9% on the same quarter a year earlier. Net income was -$8 million, and diluted earnings per share $-0.19. The figures are the company's own, from the 10-Q it filed with the SEC on 2 April 2026.

Revenue$78 millionup 8.9%
Net income-$8 million
Diluted EPS$-0.19
QuarterQ3 FY2026ended 28 February 2026

The quarter, against the one before and a year earlier

LineQ3 FY2026Q2 FY2026Q3 FY2025Change on the year
Revenue78.479.472.0+8.9%
Cost of revenue36.934.633.1+11.5%
Gross profit41.544.838.9+6.7%
Gross margin52.9%56.4%54.0%
Research and development7.17.86.9+2.5%
Operating income-13.0-6.1-10.0n/a
Operating margin-16.5%-7.7%-13.9%
Pre-tax income-8.1-6.4-4.4n/a
Income tax0.0-0.0-0.0n/a
Net income-8.1-6.3-4.4n/a
Net margin-10.3%-8.0%-6.1%
Diluted EPS-$0.19-$0.15-$0.11n/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ3 FY2026Q2 FY2026Q3 FY2025Change on the year
Operating cash flow-3.14.7-13.2n/a
Capital expenditure1.00.41.8-43.5%
Free cash flow-4.14.2-15.0n/a
Free cash flow margin-5.3%5.3%-20.8%
Cash from investing-1.5-1.6-3.2n/a
Cash from financing0.6-0.17.1-91.3%
Depreciation and amortisation5.65.76.3-11.5%
Share-based compensation2.72.92.4+12.5%
Buybacks0.00.00.0n/a
Diluted shares, weighted42m42m41m+1.8%
Shares outstanding at period end42m42m41m+1.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ3 FY2026Q2 FY2026Q3 FY2025Change on the year
Shareholders' equity173176186-6.7%
Debt0.00.00.0n/a
Operating lease liabilities4.24.52.6+62.6%
Other liabilities83.188.997.0-14.3%
Total liabilities and equity261270285-8.7%
Fixed assets29.130.532.5-10.4%
Intangible assets65.566.770.9-7.7%
Cash and equivalents37.841.644.8-15.5%
Receivables45.644.443.5+4.8%
Inventory58.665.663.1-7.2%
Other assets24.120.830.6-21.3%
Total assets261270285-8.7%

Questions

What was Angiodynamics' revenue in Q3 FY2026?

Angiodynamics (ANGO) reported revenue of $78 million for Q3 FY2026, the quarter ended 28 February 2026, up 8.9% on the same quarter a year earlier.

How much did Angiodynamics earn in Q3 FY2026?

Net loss for Q3 FY2026 was $8 million, and the diluted loss per share $0.19.

When did Angiodynamics report Q3 FY2026 results?

Angiodynamics filed its 10-Q for the quarter ended 28 February 2026 with the SEC on 2 April 2026.

Quarterly results, the last 20 quarters

Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026 †Q2 FY2026Q3 FY2026Q4 FY2026 *Q1 FY2027
Revenue78.374.087.081.585.480.791.178.779.175.271.067.572.872.080.275.779.478.486.680.9
Cost of revenue37.735.440.539.240.440.244.738.638.839.332.530.832.933.137.933.934.636.939.832.9
Gross profit40.638.646.542.345.140.546.440.140.335.938.536.739.938.942.241.944.841.546.848.0
Gross margin52%52%53%52%53%50%51%51%51%48%54%54%55%54%53%55%56%53%54%59%
R&D8.27.37.98.36.86.97.97.98.78.26.76.36.46.96.66.47.87.18.28.0
Operating income-8.7-5.3-6.4-13.3-8.1-8.9-20.835.0-13.1-200-14.4-13.1-11.1-10.0-5.8-10.7-6.1-13.0-10.2-7.3
Operating margin-11%-7%-7%-16%-9%-11%-23%45%-17%-266%-20%-19%-15%-14%-7%-14%-8%-17%-12%-9%
Interest expense0.20.20.20.40.70.70.9-0.1-0.5-0.4-0.6n/an/an/an/an/an/an/an/an/a
Pre-tax income-8.9-5.8-6.7-13.9-9.1-9.7-21.934.9-12.6-200-14.1-12.7-10.8-4.4-6.1-10.8-6.4-8.1-11.0-7.3
Tax raten/an/an/an/an/an/an/a-32%n/an/an/an/an/an/an/an/an/an/an/an/a
Net income-8.4-5.0-13.0-13.0-8.5-9.5-21.545.9-29.0-188-13.4-12.8-10.7-4.4-6.0-10.9-6.3-8.1-11.4-7.1
Net margin-11%-7%-15%-16%-10%-12%-24%58%-37%-250%-19%-19%-15%-6%-8%-14%-8%-10%-13%-9%
Diluted EPS-$0.21-$0.13-$0.16-$0.33-$0.21-$0.24-$0.54$1.15-$0.72-$4.67-$0.33-$0.31-$0.26-$0.11-$0.15-$0.26-$0.15-$0.19-$0.27-$0.17
Operating cash flow1.9-8.88.6-24.77.51.416.0-25.95.3-12.55.0-18.32.5-13.218.8-15.94.7-3.117.5-15.3
Capital expenditure1.11.11.00.81.30.71.10.80.60.60.61.10.81.80.80.70.41.00.40.4
Free cash flow0.8-9.97.5-25.66.20.714.9-26.74.7-13.14.4-19.31.7-15.018.0-16.64.2-4.117.0-15.7
Buybacksn/an/an/an/an/an/an/a0.00.00.00.00.61.10.00.00.00.00.00.0n/a
Shares outstanding39m39m39m39m40m40m40m40m40m40m40m41m41m41m41m41m42m42m42m42m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 28 February 2026, filed 2 April 2026: the filing.